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A B S T R A C T   
Introduction: Over half of the 1.5 million individuals globally who are diagnosed with colorectal cancer (CRC) 
present with stage II-III disease. Understanding clinician attitudes towards treatment for this group is paramount 
to contextualise real-world outcomes and plan future trials. The aim of this study was to assess clinician 
awareness of trials assessing the optimal duration of CRC adjuvant therapy, their attitudes towards shorter 
treatment and their self-reported practice. 
Methods: A survey was developed using OnlineSurveys® and distributed to clinicians in April 2019, with a 
follow-up survey disseminated to a subset of respondents in August 2020. Microsoft Excel® and Stata® were used 
for analysis. 
Results: 265 clinicians replied to the first survey, with the majority aware of findings from the International 
Duration Evaluation of Adjuvant Therapy collaboration and contributory trials. Practice change was greatest for 
patients under 70 with low-risk stage III CRC, with most uncertainty around using 3-months of doublet 
chemotherapy for high-risk stage II disease. In August 2020, clinicians (n = 106) were more likely to use 3- 
months of FOLFOX for low-risk stage III disease and 3-months of CAPOX for stage II disease compared to 
April 2019. There was no indication that the COVID-19 pandemic had enduring changes on treatment decisions 
beyond those made in response to trial evidence. 
Discussion: Clinicians use a risk-stratified approach to treat CRC the adjuvant setting. Lower utilisation of doublet 
chemotherapy for older and stage II patients has affected the extent of trial implementation. Active dialogue 
regarding how trial results apply to these groups may improve consensus.   
Introduction 
The findings from six clinical trials comparing 3 months of 
fluoropyrimidine-oxaliplatin chemotherapy to the standard duration of 
6 months of treatment in the adjuvant setting for stage II and/or stage III 
colon cancer have been reported since June 2017. Results from these 
trials were pooled within the International Duration of Adjuvant 
Chemotherapy (IDEA) stage II[1] and stage III [2] collaborations. Stage 
III results were initially disseminated at the American Society of Clinical 
Oncology (ASCO) conference in June 2017, published in full in March 
2018 [2], and updated in June 2020 [3]., [4] The stage II collaboration 
findings were disseminated at ASCO 20,191 and published in full in 
January 2021 [5]. Although neither of the IDEA collaborative results 
met their pre-specified non-inferiority primary end-point, the difference 
between 3 versus 6 months of chemotherapy was small, and toxicity was 
significantly reduced in the shorter treatment arm. A pre-planned IDEA 
sub-group analysis revealed an unexpected difference in the effect of 
shortened treatment duration between regimens. Non-inferiority in 
three-year disease free survival (3y-DFS) was met in patients treated 
with CAPOX but not for those prescribed FOLFOX. It has been 
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hypothesised that this may be due to a discrepancy in fluoropyrimidine 
drug intensity and mode of administration, or oxaliplatin scheduling 
between the two regimens, [4] or alternatively that differences in 
response to CAPOX versus FOLFOX may be due to a biological difference 
in tumour biology [6]., [7] A post-hoc analysis showed differences in 
outcomes for patients with stage III colon cancer depending on risk 
stratification. Non-inferiority in 3y-DFS was met for the 60% of patients 
with less locally advanced tumours and a low nodal disease burden 
(T1–3N1), referred to as “low-risk”, but for the 40% with either T4 
and/or N2 disease (“high-risk”), 6 months was superior. The Short 
Course Oncology Treatment (SCOT) trial, which recruited patients from 
six countries, was the largest contributor to IDEA stage III, one of the 
four trials that contributed to the stage II collaboration and the only trial 
that included rectal cancer patients [8]. 
There has been interest in if and how these clinical trial results have 
been interpreted by clinicians and how they have impacted on practice 
[9-11]. Previous published surveys of clinician opinion have been per-
formed before the full trial results were published [26], orfocused on a 
small group of experts[9], one country[12] and/or on stage III colon 
cancer alone[13]. It is not clear if treatment preferences have changed 
over time since 2017, nor what influence the COVID-19 pandemic has 
had. 
The aim of this study was to explore, at two separate time points 
sixteen months apart, the attitudes and self-reported clinical practice of 
medical professionals who prescribe adjuvant CRC chemotherapy. The 
objective was to understand how the IDEA collaboration and contribu-
tory trials have impacted on practice, to understand if this impact 
evolved over time and to assess any impact of the COVID-19 pandemic 
on treatment choices. 
Methods 
Online Surveys® was used for development, piloting (n = 24 pilot 
survey completion) and dissemination of a survey to ask clinicians about 
their opinions and practice. The responses from the pilot surveys were 
not formally evaluated and instead were used for testing validity and 
structure of the survey only. The final survey included four sections: i) 
Clinical trials and guidelines ii) Current practice iii) Attitudes towards 
using 3 months of adjuvant doublet chemotherapy for colorectal cancer 
(CRC), and iv) personal clinical practice details. All participants 
confirmed that they prescribed adjuvant CRC chemotherapy. Current 
practice at the time of survey completion was investigated using twelve 
hypothetical patient scenarios, six in which patients were aged under 70 
years old and six in which patients were aged 70 years or older. A list of 
these scenarios is provided in Table S1. Scenarios relevant to stage II 
disease were separated by molecular disease characteristics. Specif-
ically, scenarios describing stage II patients with tumours deficient in 
mismatch repair (MMR) proteins (dMMR) which are characterised by 
high levels of micro-satellite instability (MSI-H), were distinguished 
from patients with tumours proficient in MMR proteins, also known as 
micro-satellite stable (MSS) tumours [14]. Patients with stage II dMMR 
CRC tumours have better survival [15] but appear to respond less well to 
fluoropyrimidine chemotherapy compared to patients with pMMR tu-
mours. MMR status does not appear to predict response to 
oxaliplatin-based treatment [15]. 
A pre-specified list of UK-based CRC oncologists was collated and 
used as the primary distribution list in the UK (n = 247). The main 
reason for using this list was to enable calculation of a UK response rate. 
It was not possible to collate a similar list for all countries external to the 
UK and instead dissemination to other countries relied on a generic link 
embedded in email correspondence which was sent to all relevant pro-
fessional contacts of the study team, social media (Twitter®) and dis-
tribution lists from medical organisations (European Society for Medical 
Oncology GI, Clinical Oncology Society of Australia and the UK Royal 
College of Radiologists). 
All survey respondents were asked if they would be willing to be 
contacted again and those who agreed were sent a follow up survey in 
August 2020. Any respondents to the follow up survey had therefore 
already answered the first survey and there were no new individuals 
invited to participate at the second time point. The same questions from 
the first survey regarding the acceptability of 3 months of doublet 
chemotherapy were included. The same patient scenarios were used 
except it was specified that patients had colon cancer rather than CRC. 
Also, stage II scenarios were separated into T3N0 and T4N0 (Figure S1). 
In the second survey, clinicians were asked to respond to patient sce-
narios initially disregarding the impact of COVID-19 and then asked to 
repeat the questions indicating changes in their practice due to the 
pandemic. In these answers, respondents were asked to indicate 
enduring changes that were likely to be maintained in their future 
practice, rather than temporary changes they made during the first peak 
of the pandemic. Responses to the second survey were linked to re-
sponses to survey one from the same participants. 
The first survey was disseminated in April 2019 and kept open for 6 
weeks. The follow-up survey was distributed solely by email, kept open 
for 6 weeks and two reminder emails were sent. Descriptive statistics 
and two-sided Chi[2] or Fisher’s exact tests for proportions were per-
formed using Microsoft Excel 2016 ® and STATA v14 ®. Analysis of free 
text answers is not included in this manuscript. 
Results 
In total, 265 clinicians responded to the first survey. Respondents 
were from UK/Europe (180/265, 68%), USA/Canada (36/265, 14%), 
Asia (26/265, 10%), Australia/New Zealand (20/265, 8%), South 
America (2/265, 1%) and Africa (1/265, 0.4%) (Figure S2). The 
response rate from the pre-specified list of UK oncologists was 51% 
(126/247). Table S3 describes the characteristics of respondents. The 
majority were oncologists (258/265, 97%); most had been practicing in 
the field of oncology for at least 10 years (196/265, 74%) and the ma-
jority treated only or predominantly patients with CRC (215/265, 81%). 
In total, 106/197 (54%) of clinicians who agreed to be contacted and 
confirmed they still treated patients with CRC in August 2020, 
completed the follow up survey. They were from the UK/Europe (83/ 
106, 78%), USA/Canada (12/106, 11%), Australia (6/106, 6%), Asia (4/ 
106, 4%) and South America (1/106, 1%). 
Clinical trial findings and guidelines 
In April 2019, most clinicians (252/265, 95%) reported they were 
aware of clinical trial findings reported in the previous two years which 
assessed the optimal duration of adjuvant CRC and they almost exclu-
sively named clinical trials which contributed to the IDEA collaboration 
(Fig. 1a). A comparison of studies named by participants located in the 
UK versus countries outside the UK is shown in Figure S3 in the Sup-
plementary material. Clinicians from the UK were most likely to name 
the SCOT trial, whereas those from countries outside the UK were more 
likely to name the IDEA collaboration and/or its contributory trials. 
Overall, 87% (231/265) indicated they used international/national 
guidelines and 72% (191/265) that they used local guidelines when 
deciding how to treat CRC patients in the adjuvant setting. Fig. 1b shows 
the national guidelines that respondents indicated they use. 
Practice change in response to trial findings 
The majority of respondents (243/265; 92%) reported they had 
changed their practice in response to the findings of the trials they had 
named. The mechanisms of dissemination of trial results that most 
influenced practice were conference presentations (61%), journal pub-
lications (54%) and discussions with colleagues (49%) (Figure S4). 
Clinicians who reported no practice change (n = 19) indicated the most 
common barriers were: a) the strength of evidence provided by recent 
clinical trials (13/19), b) no existing clinical guidelines to support a 
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practice change (2/19), c) their colleagues had not changed their 
practice (2/19) and d) they had not treated any patients yet who spe-
cifically fitted the trial criteria (1/19). The final clinician had changed 
their practice prior to the release of the trials’ results. 
In the second survey, clinicians were asked in more detail to describe 
if, and when, they changed their practice in response to clinical trials. 
Ninety-eight percent (104/106) reported practice change specifically for 
patients with stage III, dropping to 58% (62/106) for stage II disease. For 
stage III disease, the full publication of the IDEA collaboration results in 
March 2018 had the biggest influence on practice, whereas for stage II 
disease there was a more even split between the pre-specified timings 
provided (Figure S5). 
Clinician attitudes towards using shorter treatment 
In April 2019, most clinicians agreed that 3 months of CAPOX was an 
acceptable standard of care for patients with low-risk stage III CRC (241/ 
265, 91%) (Fig. 2). The strongest disagreement (214/265, 81%) was 
with the statement that 3 months of FOLFOX was a standard of care for 
Fig. 1. Clinical trials (a) and clinical guidelines (b) named by survey respondents a) Clinicians were asked to specify which clinical trials they were aware of 
that had investigated the optimal duration of adjuvant chemotherapy for CRC and reported results in the previous two years, without being given a pre-specified list. 
Y-axis: Percentage of survey respondents. “Other” free text answers: “ACTS CC 02 trial”, “SAFFA” and “Japanese trial testing 1 year of treatment but not doublet”. b) 
Clinical guidelines names by respondents when asked which national guidelines they use to inform their practice (pre-specified list and respondents could choose 
more than one answer). X-axis: Percentage of survey respondents. “Other” free text answers: National Health and Medical Research Council guidelines in Australia, 
Danish Colorectal Cancer Group guidelines, German S3 guidelines, Greek national guidelines, Japanese Society for Cancer of the Colon and Rectum guidelines, Dutch 
national guidelines and guidelines from the Swedish Society of GI-Oncology. Abbreviations: SIGN, Scottish Intercollegiate Guidelines Network; NICE: The National 
Institute for Health and Care Excellence; NCCN, National Comprehensive Cancer Network; JSMO, Japanese Society of Medical Oncology; INCa, Institut National du 
Cancer; ESMO, European Society for Medical Oncology; AIOM, Associazione Italiana di Oncologia Medica . 
Fig. 2. Clinician agreement with statements that 3 months of doublet chemotherapy can be considered a standard of care treatment by disease stage and 
regimen. All patients with stage II disease assumed to have stage II disease with high-risk features if they are receiving adjuvant chemotherapy. 
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high-risk stage III disease. Although most clinicians disagreed with 
accepting 3 months of CAPOX (119/265, 45%) or FOLFOX (164/265, 
62%) as a standard treatment for stage II CRC with high-risk features, 
approximately one quarter indicated uncertainty around these 
statements. 
Fig. 3 demonstrates that clinician (n = 106) opinions generally 
remained consistent between April 2019 and August 2020. The largest 
changes were a shift from disagreement to agreement (13/106, 12%) 
that 3 months of FOLFOX could be an acceptable standard of care for 
patients with low-risk stage III disease, alongside an increase in agree-
ment that 3 months of CAPOX is an acceptable standard of care for stage 
II disease with high-risk features. There was a corresponding rise in 
disagreement with 3 months of FOLFOX as a standard treatment for 
stage II disease. 
Clinical scenarios  
(i) Patients aged under 70 
Fig. 4 shows the regimen (Fig. 4B) and duration (Fig. 4A) of treat-
ment chosen by respondents to survey one for scenarios describing pa-
tients aged under 70. The majority indicated they used CAPOX (85%; 
225/265) and 3 months (85%; 227/265) duration for patients with low- 
risk stage III CRC. For high-risk stage III scenarios, CAPOX was also the 
preferred regimen (average 67% across three scenarios) but clinicians 
were more likely to use 3–6 or 6 months (84%) compared to 3 months 
(16%). There were no significant difference in duration (2 p = 0.245) or 
regimen (2 p = 0.885) between the T4N1, T3N2 or T4N2 scenarios. 
Breaking down these results further (Supplementary Figure S6), the 
proportion of clinicians specifically choosing 3 months of doublet 
chemotherapy was 86% for the low-risk stage III scenario and on 
average, 16% for the three high-risk stage III scenarios. 
Regarding patients with stage II MSS disease, capecitabine mono-
therapy was the most common regimen chosen (135/265, 51%), fol-
lowed by CAPOX (72/265, 27%). Over 3 months was the preferred 
duration for the majority of clinicians (187/265, 71%). For the MSI-H 
stage II patients, active monitoring (157/265, 59%) was the preferred 
strategy. Focusing on potential practice change relating to the IDEA 
collaboration and contributory trials, in April 2019, 16% (82/529 re-
sponses) of clinicians chose 3 months of doublet chemotherapy for pa-
tients with stage II disease, 20% for MSS disease and 12% for MSI-H 
disease (Figure S6). 
The differences in treatment choices between participants based in 
different locations are shown in Figure S13. Across all locations, 3 
months duration was the preference for low-risk stage III disease, with 
over 3 months of treatment being the preferred duration for high-risk 
stage III disease, in particular for patients with T4N2 tumours. For 
stage III CRC, doublet chemotherapy was the primary regimen chosen. 
Clinicians from the UK, Europe and Asia preferred CAPOX for all stage III 
scenarios, whereas individuals from the USA and Australia preferred 
Fig. 3. Change in individual clinician opinions between April 2019-August 2020 for the group of clinicians who answered both surveys (n ¼ 106). Any 
changes >10% are highlighted. The coloured bars within the diagrams are not significant. 
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CAPOX for low-risk stage III disease but FOLFOX for high-risk tumours. 
When treating stage II MSS, clinicians from the UK, Europe and Australia 
used capecitabine monotherapy most often, whereas those from the USA 
preferred FOLFOX and those from Asia preferred CAPOX; over 3 months 
of treatment was the preferred duration across locations. Stage II MSI-H 
patients were mainly treated with active monitoring regardless of 
location of the treating clinician.  
(i) Patients aged 70 and over 
The responses to the same scenarios for patients aged 70 and over 
(Fig. 4C/D) indicated similar overall preferences as for younger patients 
but more heterogeneity in the choice of regimen. Although CAPOX 
(163/265, 62%) and 3 months of treatment (158/265, 60%) were again 
the most common choices for low-risk stage III disease, fluoropyrimidine 
monotherapy was selected by over one quarter of respondents (71/265, 
27%) versus 3% (7/265) for patients aged under 70 (Fisher’s exact 
p<0.001). The same pattern was seen for the high-risk stage III sce-
narios, with fluoropyrimidine monotherapy chosen by 25% of clinicians 
Fig. 4. Clinical scenario responses. A: Duration of treatment chosen by clinicians for six scenarios describing patients aged under 70 years. B: Regimen chosen by 
clinicians for six scenarios describing patients aged under 70 years. C: Duration of treatment chosen by clinicians for six scenarios describing patients aged 70 years 
and over. D: Regimen chosen by clinicians for six scenarios describing patients aged 70 years and over. E: Self-reported practice change in response to named clinical 
trials relating to the treatment choices respondents answered for the twelve patient scenarios. 
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(200/795 responses over three scenarios). For stage II MSS and MSI-H 
disease, active monitoring was used more often than for younger pa-
tients (MSS: 22% vs 8%, 2 p<0.001; MSI-H: 68% vs 59%, 2 p<0.047). 
Overall, the proportion of clinicians choosing 3 months of doublet 
chemotherapy was 54% (143/265) for low-risk stage III disease and on 
average 15% (123/795 responses) for the three high-risk stage III sce-
narios. In total 9% of clinicians (49/530 responses) chose 3 months of 
doublet chemotherapy for stage II scenarios, 8% (22/265) for MSS dis-
ease and 10% (27/265) for MSI-H disease (Figure S7). 
The differences in practice for respondents from distinct locations for 
these scenarios describing patients aged 70 and over are show in 
Figure S14 in the Supplementary material. As for scenarios describing 
younger patients, there was a strong preference for CAPOX for all stage 
III scenarios from clinicians in Asia and the UK, and a preference for 
FOLFOX rather than CAPOX for those from Australia and the USA. There 
was a more equal distribution of responses between CAPOX and FOLFOX 
for respondents from Europe compared to scenarios describing younger 
patients, where the preference was for CAPOX. For stage II disease, any 
differences in preferences between locations were similar to those 
described for younger patients.  
(i) Extent of practice change 
Clinicians indicated if their treatment preferences for the twelve 
scenarios represented a change in practice attributable to the clinical 
trials they had named. Fig. 4E demonstrates that the extent of change in 
practice aligned with the preference for 3 months of doublet treatment: 
highest for low-risk stage III disease, lowest for stage II disease and 
higher across all scenarios for younger patients. Respondents were also 
asked how representative their responses to the scenarios would be if the 
patients specifically had a diagnosis of rectal cancer. In total, 243/265 
(92%) of clinicians confirmed that they treat patients with rectal cancer 
and 140/243 (58%) indicated they use the same management strategies 
for rectal cancer patients as they chose for the twelve patients’ scenarios.  
(i) Change in practice over time 
When presented with the same clinical scenarios in August 2020, the 
biggest change in individual clinician choice (n = 106) compared to 
April 2019 was an increase (24%, 50/212) in the use of 3 months of 
treatment for patients with stage III disease with one high-risk feature 
(T4 or N2) (Fig. 5B). There was a corresponding switch by 12% (26/212 
responses) from using FOLFOX to CAPOX for the same scenario. A 
similar but less frequent switch was seen for the T4N2 scenario with 10% 
of clinicians shortening duration of treatment and 9% switching from 
FOLFOX to CAPOX. A breakdown of responses for high-risk scenarios by 
location of respondents is outlined in Table S4. For patients with T4 or 
N2 disease, the majority (55%) of UK clinicians chose shorter treatment 
(3 months), whereas over 3 months of treatment was the preference for 
those from other locations. CAPOX was the preferred regimen for all 
locations except the USA. For scenarios describing patients with T4N2 
disease, the preference for longer treatment was demonstrated across all 
locations. Regimen preferences according to location remained un-
changed from scenarios with one high-risk feature. Changes in indi-
vidual treatment choices were similar for scenarios describing older 
patients (Figure S7). 
It was not possible to compare stage II responses between the time- 
points because of the separation of scenarios to differentiate T3 and 
T4 disease in the second survey. The responses from August 2020 
however did highlight the influence of tumour stage in dictating treat-
ment choices (Figure S8). For patients with T3N0 MSS disease, clinicians 
in 2020 were significantly more likely to use active monitoring (28% 
versus 4%, Fisher’s p<0.001) and less likely to use 3 months of doublet 
chemotherapy (16% versus 34%, Fisher’s p = 0.004) compared to T4N0 
MSS disease. For MSI-H disease, in both April 2019 (67%) and August 
2020 (90% T3 and 55% T4), active monitoring was the preferred 
management strategy irrespective of T stage. CAPOX for 3 months was 
the second most common treatment choice for MSI-H stage II disease at 
both time-points (10% in 2019 and 27% (T4N0)/8% (T3N0) in 2020). 
Similar treatment patterns were chosen for patients aged 70 and over 
Fig. 5. Switch in individual treatment choices 
for scenarios describing patients with stage III 
disease aged under 70. The left side of each 
graph displays the treatment choices in April 
2019. The right side of the graphs depict the 
treatment choices for the same group of clinicians 
(n = 106) in August 2020. If an individual has 
changed their choice this is shown by a diagonal, 
rather than straight connecting grey line. Changes 
relevant to 10% or more clinicians are high-
lighted. The coloured bars within this diagram are 
not significant.   
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(Figure S9) 
The impact of the COVID-19 pandemic 
The treatment choices of clinicians that answered the second survey 
based on clinical trial evidence alone and choices from the same clini-
cians accounting for changes due to the pandemic were compared. There 
were no significant (p<0.05) enduring changes in practice due to the 
COVID-19 pandemic for any of the patient scenarios/treatment choices. 
Additional questions 
In the second survey, additional questions explored clinician practice 
in more detail. Overall, 72% (76/106) of respondents indicated they 
used the post-hoc stage III risk stratification identified by the IDEA 
collaboration and contributory trials when making treatment choices; 
34% (26/76) indicated they sub-divide this stratification further. More 
clinicians indicated they used doublet chemotherapy for treating stage II 
disease irrespective of age after the results of the IDEA collaboration 
were known compared to prior to the dissemination of the IDEA findings 
(Figure S11). 
A minority of respondents indicated they never used doublet 
chemotherapy for patients with stage II disease (16% (17/106) for pa-
tients aged under 70, 29% (31/106) for patients aged 70+). Clinicians 
were asked if they ever intentionally prescribe 3 months of fluoropyr-
imidine monotherapy and 22% (23/106) indicated they use this treat-
ment strategy. 
Finally, the majority (92%, 98/106) of respondents reported they use 
biological rather than chronological age when treating patients aged 70 
years and over and when asked to estimate the proportion of patients 
they treat that are able to continue working full time during treatment 
there was a large spread of answers (Figure S12). 
Discussion 
A critical aim of clinical cancer research is that clinical trial findings 
lead to real world health benefits. For this health impact to occur, cli-
nicians must conclude that trial findings indicate or confirm a novel 
treatment approach compares favourably to standard care, they must 
change their practice in line with trial results and be free to do so within 
the institutional constraints in which they practice. This study has pro-
vided clear evidence that a large sample of practising clinicians are 
aware of the findings of the IDEA collaboration and contributory trials 
and have changed their practice in response to those findings. It has 
previously been estimated that it takes an average of eight years for 
cancer research findings to influence clinical guidelines [16], an impact 
which one might assume pre-dates practice change. This study showed 
that in April 2019, one year after the IDEA collaboration results were 
published in full, medical professionals had already changed their 
practice, even before many of the guidelines they use had been updated. 
The change in practice was not exhaustive for all patients treated in 
the adjuvant setting. These trials had a bigger impact on prescribing for 
stage III disease, and in particular for patients with low-risk stage III 
disease. When deciding to investigate the change in practice at two time- 
points, it was hypothesised that the acceptability of 3 months duration of 
treatment may increase given that maturation of results revealed little 
clinical difference survival outcomes between 3 versus 6 months of 
treatment [4]. Indeed, there was a small shift in attitudes that aligned 
with the new data that was published during the intervening period. For 
example, the increase in clinicians accepting 3 months of CAPOX for 
stage II and the decrease in those considering 3 months of FOLFOX as a 
standard of care treatment for stage II aligned with the subgroup anal-
ysis from stage II IDEA, disseminated at ASCO in June 2019 [1]. There 
was also a rise in clinicians agreeing that 3 months of FOLFOX was 
acceptable for low-risk stage III disease, in line with updated IDEA re-
sults which confirmed a minimal difference in 5 year OS between these 
treatment arms [3]. Despite this change, in the 2020 survey, a small 
minority of clinicians chose 6 months of doublet chemotherapy as their 
first choice for managing patients with low-risk stage III disease despite 
clinical[4] and health economic evidence[17] indicating minimal OS 
difference yet much improved toxicity and better cost-effectiveness from 
shorter treatment. 
Clinicians indicated they were less likely to have changed practice 
for patients with stage II disease. The stage II IDEA findings published in 
abstract form aligned closely with results for the stage III population [1], 
therefore, the reduced uptake of study results into practice may reflect a 
lower use of doublet chemotherapy in this setting rather than the 
strength of this trial evidence. Indeed, in the August 2020 survey, some 
clinicians indicated they never used doublet treatment for patients with 
stage II disease. The avoidance of doublet chemotherapy in this context 
may be influenced by the results of previous trials, such as the subgroup 
analysis from the Multi centre International Study of Oxaliplatin/-
Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer 
(MOSAIC) study which failed to confirm an overall survival advantage 
from adding oxaliplatin to fluorouracil specifically for stage II patients 
[18]., [19] 
Our study has shown that patients with stage II MSI-H disease, 
regardless of age, are more likely to be offered doublet treatment or 
avoid adjuvant therapy altogether. This aligns with the results of pre-
vious clinician surveys, [20] and strengthens the case for ensuring this 
information is available to clinicians at the time of decision making. It 
also indicates that recent trials investigating shorter duration of doublet 
treatment are specifically more likely to influence prescribing for MSI-H 
rather than MSS stage II disease for which proportionally, doublet 
chemotherapy is used less. Overall, there was more heterogeneity in 
treatment approaches and more uncertainty regarding the acceptability 
of using 3 months of doublet chemotherapy for stage II compared to 
stage III CRC. This highlights an opportunity for clinicians to improve 
certainty in this area by increasing dialogue around the approach to 
treatment of this group. It also may encourage clinician trialists 
responsible for the stage II IDEA collaboration to focus on dissemination, 
and interpretation of those results in the context of previous trials 
assessing the merits of using doublet treatment in this patient cohort. 
The extent of self-reported practice change in response to recent 
trials was less for older versus younger patients, concurring with results 
from a survey of French clinicians (n = 213) [12]. Reduced impact on 
practice for older patients is likely to again reflect the less frequent use of 
doublet chemotherapy for older versus younger patients generally. This 
may be due in part to previous individual and pooled trial subgroup 
analyses showing a lack of benefit from adding oxaliplatin to fluo-
ropyrimidine for older patients, [18], [19], [21] although there are re-
ports that some benefit of oxaliplatin may be maintained in older the 
older age group [22-24]. An age cut-off of 70 years was chosen for the 
practicalities of survey development, but the vast majority of clinicians 
indicated they use biological rather than chronological age when mak-
ing treatment decisions. Therefore, it is acknowledged that clinicians are 
unlikely to alter their practice across such a strict age cut off in real life. 
This reflects the difficulty with making any treatment decisions based on 
age alone and explains why most national guidelines from professional 
bodies (NCCN, ESMO, ASCO) do not mention age. Recently updated 
NICE CRC guidelines do mention that age is taken into consideration but 
do not give direction on how this may specifically affect treatment 
choices [25]. In the second survey, a minority of clinicians indicated 
they intentionally use 3 months of adjuvant fluoropyrimidine mono-
therapy in some circumstances. The SAFFA trial [27] compared 3 
months of protracted venous infusion 5-fluorouracil against 6 months of 
bolus 5-FU/leucovorin in patients with stage II/III CRC and showed 
there was no OS difference between the treatment arms. This strategy 
has not yet been tested using modern infusional regimens, such as 
modified deGramont, in both arms, nor with the orally administered 
drug capecitabine. Further investigation into clinician opinion would be 
helpful to understand the decision making process of those who 
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routinely use 3 months of monotherapy; for example are they consid-
ering and applying just the results of the SAFFA trial, are they extrap-
olating the results of the IDEA collaboration, or are they using the results 
from both trials simultaneously to inform treatment choice. 
Treatment preferences differed by location and our results support 
those from a previous study by Iveson and colleagues[26]. Specifically, 
there was a preference for using CAPOX rather than FOLFOX treatment 
in the Europe and Asia, in particular for high-risk stage III disease, 
whereas the reverse was true for clinicians from Australia and the USA. 
As in the survey by Iveson et al.[26], there was low representation in this 
study from European clinicians from France and Italy. Given that cli-
nicians demonstrated a preference for FOLFOX rather than CAPOX when 
recruiting to the IDEA-France and Italian TOSCA trial, higher numbers 
of survey respondents from these locations may have altered the Euro-
pean preference for CAPOX. Also aligning with the results from the 
previous survey[26], European, and in particular UK clinicians in our 
study, were more likely than those from other locations to change 
practice to use 3 months of treatment across the stage III scenarios. 
The COVID-19 pandemic undoubtedly influenced chemotherapy 
prescribing during the first peak [28]., [29] Encouragingly, our study 
shows that, if dependant on clinician preference alone and not con-
strained by institutional policies, there are unlikely to be significantly 
enduring changes due to COVID-19 going forward that differ from 
practice decisions based on clinical trial evidence alone. 
Finally, we asked an exploratory question to garner estimates from 
clinicians about the impact of adjuvant treatment on patients’ ability to 
return to work, in the hope that this may provide insight into the po-
tential societal impact that shortening the duration of adjuvant CRC 
treatment may have on productivity. This question showed a wide range 
of answers; either the range of patients continuing to work is truly 
heterogeneous across different locations or this is unknown and difficult 
to estimate for clinicians. A “don’t know” option was not included. 
Prospective surveys of patients themselves could be used to explore this 
issue. 
There are limitations to this study, some of which are inherent to 
survey methods. This study surveyed a sample of clinicians, so there may 
be response bias, where respondents may have been more engaged with 
research, more likely to be aware of trial findings and more motivated to 
change practice compared to non-responders. The study did not focus 
specifically on rectal cancer patients and how treatment decisions may 
vary compared to colon cancer; so this may warrant further investiga-
tion. There were four separate patient scenarios for each patient age 
group with stage III disease used in these surveys, however there are 16 
possible combinations of stage III disease dependant on T and N stages, 
with differences in survival between each combination [30]. In a real 
world setting treatment choices may be diluted based on patient, disease 
and other external variables. For this reason, an analysis of actual pre-
scribing records could be a stronger indicator of current overall practice, 
although this would not give insights into clinicians’ decision-making 
processes. Lastly, larger and more even numbers of respondents from 
different locations would have made any between country comparisons 
more reliable. 
In conclusion, the IDEA collaboration and contributory trials have 
impacted on clinician attitudes and changed self-reported practice. 
Across several countries, CRC patients are now being offered shorter 
durations of adjuvant treatment, leading to the health benefits of less 
toxicity whilst maintaining survival gains. Trial sub-group analyses, as 
well as pre-existing attitudes towards using doublet chemotherapy in 
certain disease/patient scenarios (stage II/aged 70+) have influenced 
the proportion of patients who will be affected by the IDEA collaboration 
and contributory trial findings. It is likely that chemotherapy prescrib-
ing will have been significantly affected during the first peak of the 
COVID-19 pandemic, but based on our survey, we found that the 
pandemic is unlikely to have a significant enduring impact on practices 
relevant to this patient cohort. The results of this study will show cli-
nicians how their colleagues in different countries are interpreting and 
applying trial results and will add to the dialogue regarding adjuvant 
treatments delivered in real world settings and the approaches that 
should be used as the control arm for clinical trials for patients with CRC 
going forward. 
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